Cargando…
Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe
Background: Creating new therapies often involves drug companies paying healthcare professionals and institutions for research and development (R&D) activities, including clinical trials. However, industry sponsorship can create conflicts of interest (COIs). We analysed approaches to drug compan...
Autores principales: | Ozieranski, Piotr, Martinon, Luc, Jachiet, Pierre-Alain, Mulinari, Shai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105170/ https://www.ncbi.nlm.nih.gov/pubmed/35297231 http://dx.doi.org/10.34172/ijhpm.2022.6575 |
Ejemplares similares
-
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
por: Ozieranski, Piotr, et al.
Publicado: (2021) -
Drug company payments to General Practices in England: Cross-sectional and social network analysis
por: Saghy, Eszter, et al.
Publicado: (2021) -
Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018) -
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
por: Mulinari, Shai, et al.
Publicado: (2020) -
Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)